



Telephus Medical CEO Mark Benedyk Joins Pulmotect, Inc. Board of Directors

Houston, TX (June 14, 2017) – Pulmotect, Inc., a clinical-stage biotechnology company developing PUL-042, a fast-acting pulmonary immune stimulant for the treatment of antibiotic-resistant respiratory infections, today announced that Mark Benedyk, Ph.D., President and CEO of Telephus Medical, was appointed to the Company's board of directors.

"Mark is a highly respected CEO and long-time business development strategist in both the biotech and pharma sectors," said Nestor Molfino, M.D., Pulmotect CEO. "His insight and guidance will prove invaluable as we work to commercialize Pulmotect's therapeutic assets."

"I am delighted to join the board of Pulmotect," said Dr. Benedyk. "Nestor's focus on the treatment of COPD exacerbations and other severe lung infections will bring tremendous benefits to patients who are in dire need of new therapeutic approaches such as PUL-042."

With more than 20 years of life science industry experience, Dr. Benedyk founded Telephus in 2013. Prior to Telephus, he headed The Pfizer Incubator (TPI) in La Jolla, CA where he held board positions with TPI and its portfolio companies. Before that, he held executive positions in Business Development and Intellectual Property at Ascenta Therapeutics, Optimer Pharmaceuticals (now Merck (NYSE: MRK)), Aurora Biosciences (now Vertex (NASDAQ: VRTX)) and Elan Pharmaceuticals (now Perrigo (NYSE: PRGO)). Dr. Benedyk is on the board of Accel-Rx, Canada's healthcare innovation accelerator and is an advisor to RARE Science, an organization focused on developing cures for pediatric rare diseases and to Sweetwater Capital, a capital advisory and asset management firm.

Dr. Benedyk received a PhD in Developmental Genetics from The Rockefeller University, where he was a Lucille P. Markey Graduate Fellow. His BS in Microbiology and Botany is from the University of Michigan.

In addition to Benedyk, Pulmotect's board of directors includes:

- Leo Linbeck, III, CEO of Aquinas Companies, LLC.
- Magnus Hook, Ph.D., director of the Center for Infection and Inflammation - Institute of Biosciences and Technology of Texas A&M
- Atul Varadhachary, M.D., Ph.D., managing director of Fannin Innovation Studio
- Mark Worscheh, executive vice president of Aquinas Companies, LLC.
- Bruce Given, M.D., COO of Arrowhead Research Corporation and CEO of Leonardo Biosystems

About Pulmotect, Inc.

Founded in 2007, Pulmotect is actively developing PUL-042 (a TLR 2, 6 and 9 agonist), a novel, clinical stage inhaled therapeutic for the prevention and treatment of acute, severe viral and bacterial respiratory infections in immunocompromised patients. Having demonstrated its safety in two Phase 1 clinical trials, Pulmotect will initiate a Phase 2b trial for PUL-042 in the second quarter of 2017. Pulmotect holds an exclusive, global license for the PUL-042 technology from The Texas A&M University System and The University of Texas MD Anderson Cancer Center. For more information, visit www.pulmotect.com.